Retension Pharmaceuticals raises $45m in Nasdaq IPO for RTN-001
Retension Pharmaceuticals has priced its initial public offering at $12.00 per share, raising $45 million in gross proceeds from the sale of 3,750,000 shares of common stock. The Falls Church, Virginia company began trading on the Nasdaq Capital Market under the ticker "RTSN" on 9 October 2026, with the offering expected to close around 13 October.
The IPO was upsized ahead of pricing, and underwriters have been granted a 30-day option to purchase an additional 562,500 shares at the offer price, which could lift total gross proceeds to approximately $51.75 million if exercised in full. Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers, with Titan Partners as lead manager.
Use of proceeds
Retension intends to direct the net proceeds toward completing its ongoing Phase 2b trial of its lead candidate, RTN-001, in uncontrolled hypertension, and to prepare for and advance a planned Phase 3 programme in the same indication. Any remainder will be allocated to general corporate purposes.
RTN-001 is a next-generation PDE5 inhibitor designed to enhance nitric oxide signalling in central arteries that the company says are not adequately reached by first-generation drugs in the same class. The mechanism targets a recognised driver of persistent high blood pressure in patients who do not respond adequately to existing treatment. Retension is developing RTN-001 under an exclusive worldwide licence from Sanofi. The candidate has been studied across multiple clinical trials enrolling 265 subjects in total, and two earlier Phase 2 pilot studies reported what the company describes as clinically meaningful placebo-adjusted reductions in both systolic and diastolic blood pressure.
Market context
Uncontrolled and resistant hypertension represents a substantial unmet need. Estimates from cardiovascular epidemiology studies suggest that somewhere between 10% and 20% of treated hypertensive patients fail to reach blood pressure targets on current standard-of-care regimens, a population that runs to tens of millions globally. The PDE5 inhibitor class is well established in pulmonary arterial hypertension and erectile dysfunction, but its application to systemic hypertension has seen limited commercial development, leaving Retension in a relatively uncrowded space at the clinical stage.
The company's positioning as a Sanofi licensee provides some validation for the underlying chemistry, though investors will note that Sanofi chose not to advance the asset itself. The Phase 2b readout will be closely watched: the earlier pilot data, while encouraging, came from smaller studies and did not produce the scale of evidence required to support a regulatory submission. The critical question for the Phase 3 design will be whether the blood pressure reductions seen to date translate into durable outcomes in a broader, harder-to-treat patient population.
The IPO comes during a selective but gradually recovering window for small-cap biotech listings. A number of cardiovascular-focused clinical-stage companies have sought public capital in 2025 and 2026 as investor appetite for non-oncology indications has improved modestly following several years of concentrated focus on oncology and rare disease. At a $45 million raise, Retension's debut is modest by recent standards, and management will need to demonstrate Phase 2b progress efficiently to maintain market confidence ahead of the larger capital requirements a Phase 3 trial will demand.